Home Newsfeeds Craig-Hallum Downgrades Sono Group to Hold

Craig-Hallum Downgrades Sono Group to Hold

Craig-Hallum analyst Eric Stine downgrades Sono Group (NASDAQ:SEV) from Buy to Hold.

byBenzinga Newsdesk

February 27, 2023

1 minute read

Craig-Hallum analyst Eric Stine downgrades Sono Group (NASDAQ:SEV) from Buy to Hold.

JP Morgan Downgrades Janus Henderson Gr to Underweight, Lowers Price Target to $18

By Benzinga Newsdesk

July 18, 6:29 AM

JP Morgan analyst Ken Worthington downgrades Janus Henderson Gr (NYSE:JHG) from Neutral to Underweight and lowers the price target from $27 to $18.

JHG

Korn Ferry Q1 Earnings Beat Estimates On Strength In Diversification Strategy

By Nabaparna Bhattacharya

September 7, 12:01 PM

Korn Ferry (NYSE: KFY) reported first-quarter FY23 total revenue growth of 0.5% year-over-year to $706.26 million,

KFY

Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End

By Vandana Singh

July 24, 11:10 AM

Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host di

INCY

Elon Musk Spars With Historian Over Government Subsidies, Accuses Her Of Rehashing Oil, Gas Industry’s ‘Propaganda’

By Shanthi Rexaline

October 22, 4:16 PM

Noted historian Ruth Ben-Ghiat found herself in the crossfires of billionaire Elon Musk on Saturday when she called him out for his “faux selflessness.”

TSLA

Craig-Hallum Downgrades Sono Group to Hold

Related Posts

JP Morgan Downgrades Janus Henderson Gr to Underweight, Lowers Price Target to $18

Korn Ferry Q1 Earnings Beat Estimates On Strength In Diversification Strategy

Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End

Elon Musk Spars With Historian Over Government Subsidies, Accuses Her Of Rehashing Oil, Gas Industry’s ‘Propaganda’